Sign up to save your podcasts
Or
Share Advances in AML: The Role of a BCL-2 Inhibitor in Current Treatment Paradigms
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Advances in AML: The Role of a BCL-2 Inhibitor in Current Treatment Paradigms
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
View all episodes
By ReachMD
4
11 ratings
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
More shows like Medical Industry Feature
View all
SexMed
3 Listeners
Partners in Practice
3 Listeners
Second Opinion LIVE!
0 Listeners
Medical Breakthroughs from Penn Medicine
6 Listeners
Advances in Women's Health
15 Listeners
GI Insights
18 Listeners
Conference Coverage
0 Listeners